{"id":8841,"date":"2022-01-04T12:00:15","date_gmt":"2022-01-04T12:00:15","guid":{"rendered":"http:\/\/i-base.info\/guides\/?p=8841"},"modified":"2024-08-30T14:01:57","modified_gmt":"2024-08-30T14:01:57","slug":"quad-stribild","status":"publish","type":"post","link":"https:\/\/i-base.info\/guides\/8841","title":{"rendered":"Stribild (elvitegravir + cobicistat + emtricitabine (FTC) + tenofovir DF)"},"content":{"rendered":"<p><img loading=\"lazy\" decoding=\"async\" class=\"alignnone wp-image-8846\" title=\"Quad 2013 sml\" src=\"https:\/\/i-base.info\/guides\/wp-content\/uploads\/2013\/04\/Quad-2013-sml.png\" alt=\"\" width=\"86\" height=\"45\" \/><br \/>\n<!--more--><em>STRY-BILD<\/em><\/p>\n<p><strong>Stribild was approved in Europe in May 2013 and approved by NHS England for use in the UK in September 2013. It was approved in the USA in August 2012. Prior to approval it was called Quad.<\/strong><\/p>\n<p><strong>Stribild<\/strong>\u00a0is a 4-in-1 single combination pill that is\u00a0taken once-daily, with food.<\/p>\n<p>The active drugs in Stribild are:<\/p>\n<ul>\n<li>150 mg elvitegravir <em>(el-vye-TEG-rah-vir) &#8211;\u00a0an integrase inhibitor.<\/em><\/li>\n<li>150 mg cobicistat <em>(cob-BIS-is-stat) &#8211;\u00a0a \u201cbooster\u201d for elvitegravir.<\/em><\/li>\n<li>300 mg <a href=\"https:\/\/i-base.info\/guides\/3541\">tenofovir<\/a>. (245 mg as tenofovir fumerate)<\/li>\n<li>200 mg <a href=\"https:\/\/i-base.info\/guides\/3535\">FTC<\/a>.<\/li>\n<\/ul>\n<p>In a recent update to the US DHHS guidelines Stribild is now included as a preferred first combination.<\/p>\n<ul>\n<li>Stribild needs to be taken with food. The amount of type of food is not included in this recommendation but it may be important to include fat. The food interaction study reported that\u00a0elvitegravir exposure (total drug levels over the dose period, called the AUC) increased by 36% with a light meal (~373 kcal, 20% fat)\u00a0and by 91% with a high-fat meal (~800 kcal, 50% fat).<\/li>\n<li><strong>Drug interactions<\/strong> include with antacid medicines which can reduce levels of elvitegravir. Antacids need to be be separated by at least four hours.<\/li>\n<li><strong>A potential interaction<\/strong> means that multivitamins and elvitegravir need to be separated by at least four hours.<\/li>\n<li><strong>Drug interactions. <\/strong>Please tell your doctor or pharmacist about any other drugs or supplements before taking them with Biktarvy. Drug interactions can also be checked using the online checker at Liverpool University HIV Interaction website:<br \/>\n<a href=\"https:\/\/www.hiv-druginteractions.org\/checker\">https:\/\/www.hiv-druginteractions.org\/checker<\/a><\/li>\n<li>Stribild should not be used in people with reduced kidney function defined as having eGRF levels less than 70 mL\/minute.<\/li>\n<\/ul>\n<p>The European\u00a0<em>patient leaflet<\/em>\u00a0and detailed\u00a0<em>Product Information<\/em>\u00a0for Stribild\u00a0are available from\u00a0<a href=\"https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/stribild\">this link<\/a>\u00a0on the European Medicines Agency (EMA) website.<\/p>\n<p>The\u00a0<em>Patient Information<\/em>\u00a0is a simplified summary: what the drug is, why it is used, results from studies and cautions including side effects.<\/p>\n<p>The\u00a0<em>Product Information<\/em>\u00a0is a detailed technical summary that you can access as a PDF file by clicking the \u2018Product Information\u2019 tab. It describes more precisely how the drug works and how it is processed by your body. This includes, for example, reported food interaction studies in terms of calories or fat content. It includes more details of the study results and a full list of side effects and drug interactions.<\/p>\n<p>Link to\u00a0<a href=\"http:\/\/www.gilead.com\/~\/media\/Files\/pdfs\/medicines\/hiv\/stribild\/stribild_pi.pdf\" target=\"_blank\">US prescribing information<\/a>. (PDF document)<\/p>\n","protected":false},"excerpt":{"rendered":"","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[3,6,8,10],"tags":[],"class_list":["post-8841","post","type-post","status-publish","format-standard","hentry","category-arvs","category-fixed-dose-combinations","category-integrase-inhibitors","category-nukes"],"_links":{"self":[{"href":"https:\/\/i-base.info\/guides\/wp-json\/wp\/v2\/posts\/8841","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/i-base.info\/guides\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/i-base.info\/guides\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/i-base.info\/guides\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/i-base.info\/guides\/wp-json\/wp\/v2\/comments?post=8841"}],"version-history":[{"count":1,"href":"https:\/\/i-base.info\/guides\/wp-json\/wp\/v2\/posts\/8841\/revisions"}],"predecessor-version":[{"id":17220,"href":"https:\/\/i-base.info\/guides\/wp-json\/wp\/v2\/posts\/8841\/revisions\/17220"}],"wp:attachment":[{"href":"https:\/\/i-base.info\/guides\/wp-json\/wp\/v2\/media?parent=8841"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/i-base.info\/guides\/wp-json\/wp\/v2\/categories?post=8841"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/i-base.info\/guides\/wp-json\/wp\/v2\/tags?post=8841"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}